ROCHESTER, Minn.–(BUSINESS WIRE)–INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapiesROCHESTER, Minn.–(BUSINESS WIRE)–INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies

INTENT Biologics Receives FDA Agreement Granting a Full Waiver for its Pediatric Study Plan for PEP Biologic™ in Advanced Wound Care

ROCHESTER, Minn.–(BUSINESS WIRE)–INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has agreed to INTENT’s Initial Pediatric Study Plan (iPSP) for PEP Biologic™ under IND 019567, supporting the company’s request for a full pediatric waiver for its forthcoming Biologics License Application (BLA).

FDA’s agreement reflects alignment that pediatric studies are not required for PEP Biologic’s flagship indication, diabetic foot ulcers (DFU) which is initiating a pivotal trial in 2026. The agreed iPSP provides regulatory clarity and removes the requirement to conduct clinical studies in the pediatric population as part of the DFU development program, contingent upon biologic licensure.

“FDA alignment on our pediatric study plan is another important regulatory milestone achieved as we advance PEP Biologic toward late-stage clinical development and eventual BLA submission,” said Suneet Varma, Chief Executive Officer of INTENT Biologics. “This agreement allows us to remain fully focused on delivering a first-in-class biologic therapy for adult patients suffering from DFU, one of many different chronic, non-healing wounds with significant unmet medical need, while maintaining a clear and efficient regulatory pathway.”

The pediatric waiver agreement follows the FDA’s recent Fast Track designation for PEP Biologic in diabetic foot ulcers and further strengthens INTENT’s regulatory position as the company prepares for late-stage clinical development and registration-enabling studies. Together, these achieved regulatory milestones support an efficient development strategy aligned with FDA expectations for serious adult-onset conditions where pediatric studies are impossible or highly impractical.

PEP Biologic is a platelet-derived exosome biologic designed to deliver regenerative signaling messages that modulate immune responses and promote tissue repair, supporting resolution of inflammation and tissue regeneration. INTENT Biologics is advancing PEP Biologic into clinical development for diabetic foot ulcers, chronic radiation ulcers, and advanced wound care indications based on a proprietary exosome platform originating from RION.

About PEP Biologic™

PEP Biologic (Purified Exosome Product) is a first-in-class exosome therapeutic discovered through Mayo Clinic Van Cleve Cardiac Regenerative Medicine Program and developed on RION’s industry-leading platelet-derived exosome biomanufacturing platform. Packaged as a shelf-stable lyophilized powder, each dose contains regenerative exosomes that deliver polyvalent biologic signals to induce tissue regeneration and regulate immune responses for accelerated healing. With a novel mechanism of action that reduces hyper-inflammation, regulates immune response and repairs & regenerates tissue, PEP Biologic is being advanced by INTENT Biologics into pivotal clinical trials for a range of advanced wound care indications where current treatments fail to address the underlying biology.

About INTENT Biologics

INTENT Biologics is a clinical-stage biotechnology company dedicated to developing first-in-class exosome-based therapeutics in Advanced Wound Care. Spun out of RION, a global leader in regenerative exosome science, and built on more than two decades of research at the Mayo Clinic, INTENT is advancing PEP Biologic into late-stage clinical development for multiple indications in advanced tissue regeneration. Headquartered in Minnesota, the company is focused on “revolutionizing and replacing” standards of care in chronic wounds by harnessing regenerative exosomes to treat diseases with significant unmet need. More information can be found at www.intent.bio.

About RION

RION is a clinical-stage regenerative medicine company founded out of the Mayo Clinic after two decades of stem cell and exosome research and innovation. RION is the global leader in isolating and mass-producing platelet-derived regenerative exosomes into a proprietary therapeutic platform to produce Purified Exosome Product (PEP), a shelf-stable biologic designed to activate the body’s natural healing processes. RION is advancing a deep pipeline with clinical and preclinical programs in diabetic foot ulcers, knee osteoarthritis, musculoskeletal injury, dermatologic conditions, pulmonary disease, cardiovascular health, and women’s health. RION’s regenerative PEP technology will be integral to the therapeutic exosome revolution. More information can be found at www.riontx.com.

Contacts

Investor Relations
[email protected]

Market Opportunity
PEP Logo
PEP Price(PEP)
$0.0002408
$0.0002408$0.0002408
-1.63%
USD
PEP (PEP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

SEC Delays Crypto Innovation Exemptions, Citing Further Study

SEC Delays Crypto Innovation Exemptions, Citing Further Study

SEC postpones crypto innovation exemptions for blockchain products pending further analysis and congressional input.
Share
CoinLive2026/01/31 11:15
Crypto Market Crash To 6-Month Low Amid Rising Tensions Between Iran and The US

Crypto Market Crash To 6-Month Low Amid Rising Tensions Between Iran and The US

The post Crypto Market Crash To 6-Month Low Amid Rising Tensions Between Iran and The US appeared on BitcoinEthereumNews.com. Key Insights: President Trump induces
Share
BitcoinEthereumNews2026/01/31 11:02
If you put $1,000 in Intel at the start of 2025, here’s your return now

If you put $1,000 in Intel at the start of 2025, here’s your return now

The post If you put $1,000 in Intel at the start of 2025, here’s your return now appeared on BitcoinEthereumNews.com. Intel (NASDAQ: INTC) and Nvidia (NASDAQ: NVDA) announced a new partnership on Thursday, September 18, working on several generations of custom data center and computing chips designed to boost performance in hyperscale, enterprise, and consumer applications. As part of the collaboration, Nvidia, the undisputed leader of the semiconductor sector, will also invest $5 billion in Intel by purchasing its common stock at a price of $23.28 per share. Following the news, Intel stock jumped more than 30% in pre-market trading, while Nvidia saw a 3% uptick, a welcome change following weeks of shaky performance and controversies regarding its Chinese sales. Trading at $31.34 at the time of writing, INTC shares are up 54.99% year-to-date (YTD). INTC YTD stock price. Source: Google Accordingly, a $1,000 investment in the tech company at the start of the year would now be worth $1,549.90, giving you a return of $549.90. ‘The next era of computing’ The move follows a wave of fresh backing for the struggling Intel, including a nearly $9 billion U.S. government purchase of a 10% stake just weeks ago and a $2 billion investment from Japan’s SoftBank. As such, the deal has the potential to put Intel back into the game after years of trying to catch up not just with Nvidia but also AMD (NASDAQ: AMD) and Broadcom (NASDAQ: AVGO). “This historic collaboration tightly couples NVIDIA’s AI and accelerated computing stack with Intel’s CPUs and the vast x86 ecosystem — a fusion of two world-class platforms. Together, we will expand our ecosystems and lay the foundation for the next era of computing,” wrote Nvidia founder and chief executive officer (CEO), Jensen Huang.  However, the U.S. government’s direct involvement suggests that more is at stake than simply propping up Intel, as it likely reflects a broader concern about keeping America competitive…
Share
BitcoinEthereumNews2025/09/18 22:47